Testosterone and Male Fertility: What a Low Result Means

Usually not on its own, and the reason is a measurement problem rather than a judgement call. Sperm production depends on the testosterone concentration inside the testis, which is far higher than the concentration a blood test samples. In 29 men randomised in a 2005 study at the University of Washington, serum testosterone averaged 14.1 nmol/L while the fluid drawn from inside the testis averaged 1,174 nmol/L. The blood figure was 1.2% of the testicular one.

So a blood testosterone result does not measure the thing sperm production runs on. It is a proxy, and it is a poor one in the direction that matters most: a man can have a low blood testosterone and adequate sperm production, or a normal blood testosterone and almost none.

The test that answers the fertility question is a semen analysis. The testosterone result answers a different question, about symptoms.

If your semen analysis has already come back abnormal, the next reading is what causes a low sperm count and what a semen analysis reveals.

On its own, very little. Testosterone is highest in the early morning and falls through the day, so the same man sampled at 9 am and 4 pm can cross the cut-off in one direction without anything about him having changed.

Two guidelines converge on how to handle that. The AUA Testosterone Deficiency Guideline says the diagnosis of low testosterone should be made only after two total testosterone measurements taken on separate occasions, both conducted in an early morning fashion, and that a total testosterone below 300 ng/dL is a reasonable cut-off in support of the diagnosis. The Endocrine Society guideline asks for fasting morning total testosterone on an accurate and reliable assay, then the same measurement repeated to confirm.

Two things follow from that, and they are worth being firm about before any treatment conversation:

• A single afternoon sample is not a diagnosis. If that is all you have, the honest next step is a repeat early morning test, not a prescription.
• A number without symptoms is not a diagnosis either. The Endocrine Society recommends diagnosing hypogonadism only in men who have both symptoms and signs of testosterone deficiency and unequivocally and consistently low serum testosterone. Treating a value in a man who feels well is not a goal that guideline recognises.

Total testosterone is the initial test. Free testosterone -- the fraction not bound to carrier proteins -- is a second-line measurement, useful when the total sits near the lower limit or when something is altering sex hormone binding globulin, and the Endocrine Society asks for it by equilibrium dialysis or an accurate formula rather than a direct assay. The AUA panel does not recommend free testosterone as the primary diagnostic method at all. Assay quality is not a pedantic point here: the Endocrine Society has published a separate position statement on how imprecise and method-dependent sex steroid measurement can be, written about estradiol but making the general case.

If the first result was low, the sequence is short and it is worth knowing so you can ask for it.

1. A repeat early morning total testosterone, fasting, on the same assay where possible. This is the step most often skipped.
2. Serum LH. The AUA guideline states that clinicians should measure serum luteinising hormone in patients with low testosterone. It separates a problem in the testis, where LH is high because the pituitary is pushing harder, from a problem above it, where LH is low or normal.
3. Prolactin, but only in a specific situation: the AUA guideline asks for it where low testosterone is combined with a low or low-normal LH.
4. A semen analysis, which is a separate investigation and the only one that speaks to fertility. It is not interchangeable with a hormone panel and a normal hormone panel does not make it unnecessary.

One caution about how the semen result is read. The reference limits in the WHO laboratory manual are the distribution of values seen in men whose partners conceived, not a line between fertile and infertile -- a point Bjorndahl and colleagues made explicitly in 2022, noting that these ranges and limits have been misinterpreted as distinct limits between fertility and infertility. A result slightly under a reference limit is information, not a verdict.

What the hormone results mean in combination is covered separately in FSH and LH in male infertility and what hypogonadism is.

No, and this is one of the few places in fertility medicine where the guidance is not hedged. The AUA Testosterone Deficiency Guideline, Statement 23, reads: "Exogenous testosterone therapy should not be prescribed to men who are currently trying to conceive." The Endocrine Society recommends against starting testosterone therapy in patients who are planning fertility in the near term.

The mechanism is the same one the 2005 study measured. Your brain reads the testosterone in your blood and, finding plenty, stops sending the two signals the testes need: LH, which drives your own testosterone production, and FSH, which supports sperm production. Of the 29 men randomised, those given 200 mg testosterone enanthate weekly with saline placebo had LH fall to 5% and FSH to 3% of baseline within three weeks, and in that randomised arm intratesticular testosterone fell 94%, from a baseline of 1,234 nmol/L to 72 nmol/L.

That is the same effect hormonal male contraception is designed to produce. Testosterone given to a man who wants a child is working against the outcome he came in for, and the blood test will look better while it does.

The treatment decision itself, including what testosterone therapy does help and what it has been tested for, is set out in testosterone therapy: what it does and what it costs fertility.

Do not stop a prescribed drug on your own. Stopping abruptly leaves you with neither your own testosterone production nor the replacement, and the doctor who prescribed it needs to manage the switch. Book the conversation, and go in knowing the numbers.

Here is the honest timeline. The best data on recovery comes from pooled individual results of 30 hormonal male contraception studies: 1,549 healthy men, monitored with a sperm count every single month until they recovered. The median time for sperm concentration to come back to 20 million per mL was 3.4 months. Pooled across that cohort, the probability of getting there was 67% within 6 months, 90% within 12 months, 96% within 16 months, and effectively complete by 24 months.

Two caveats make that better news than it sounds and worse news than it sounds at the same time. Better, because recovery in that pooled analysis was eventually full in essentially everyone. Worse, because those were healthy young men on controlled, monitored regimens with normal sperm counts before they started -- the most favourable possible conditions. A man who has been on testosterone for years, or who had a low count to begin with, is not represented by that curve.

Non-prescribed androgens from a gym or an online seller are the same mechanism at a larger and unpredictable dose. Across 33 studies and 1,766 users, LH fell by a weighted mean of 3.37 IU/L, FSH by 1.73 IU/L and the men's own testosterone by 10.75 nmol/L while they were using. After they stopped, gonadotropins climbed back to baseline over 13 to 24 weeks, but testosterone was still below baseline at 16 weeks, and the review also recorded structural and functional sperm changes and reduced testicular volume.

What a doctor can do in the meantime, and what the evidence for it is, is covered in anabolic steroids and sperm damage and hormonal therapy for male infertility.

In principle yes, and in practice the evidence is thinner than the confidence with which it is prescribed.

The drugs used for this -- clomiphene and other selective oestrogen receptor modulators, aromatase inhibitors, injected hCG -- work by increasing your own LH and FSH rather than replacing the end product, so they raise testosterone without switching the axis off. The AUA guideline permits them, in conditional language: clinicians "may" use aromatase inhibitors, hCG, selective oestrogen receptor modulators or a combination in men with testosterone deficiency who want to maintain fertility.

What has not been shown is that any of this changes a reproductive outcome. A 2026 systematic review in the Journal of Clinical Endocrinology and Metabolism searched to February 2025 for hormonal treatment in normogonadotropic men with abnormal semen parameters -- men whose LH and FSH are already normal, which is most men with a poor semen result. Nine studies and 735 men qualified. No eligible study evaluated clomiphene. None evaluated an aromatase inhibitor. Tamoxifen showed no benefit, and neither did combined hCG with hMG. Only FSH produced measurable semen changes, which the reviewers described as modest and short-term with uncertain translation to pregnancy or live birth.

That is not an argument for testosterone instead. It is an argument for keeping the two questions apart: treating symptoms, and trying to conceive. Clomid for men: what the evidence does and does not show goes through the clomiphene trials in detail.

When it is not making you unwell, and when it has not been confirmed. The Endocrine Society position is that hypogonadism is diagnosed in men who have symptoms and signs of testosterone deficiency together with unequivocally and consistently low serum testosterone -- both halves, not either. A borderline figure on a single sample in a man with no symptoms is a reason to repeat the test, and often a reason to stop there.

There are also situations where testosterone is a symptom rather than the problem. Weight, poor sleep, opioids, corticosteroids and uncontrolled diabetes all lower it, and treating the cause changes the number without anyone prescribing a hormone. That is a slower route and it is frequently the correct one.

And sometimes the answer for a couple is neither hormone nor hormone-blocker. If the semen result is the problem, the options that have actually been shown to produce pregnancies in that situation are the ones worth discussing -- including the possibility that nothing about your testosterone needs to change at all.

The modifiable causes are gone through in male fertility and weight and medications that affect male fertility.

Being told your testosterone is low, and then being told the obvious fix will set your fertility back, is a disorienting sequence. It is also the common one rather than a sign something was missed.

• That serum testosterone predicts sperm count. The two were measured 100-fold apart inside and outside the testis in the 2005 study, and no retrieved source establishes a usable predictive relationship between the blood level and the semen result.
• That any dose of exogenous testosterone is safe for fertility. Low-dose and microdosed regimens have not been shown to spare spermatogenesis in any source retrieved for this article. The claim circulates; the evidence for it was not found.
• That one route of administration suppresses less than another. Liu 2006 found shorter-acting preparations predicted a faster rate of recovery, and stated explicitly that covariates affected the rate but not the extent of recovery.
• That recovery figures from contraceptive trials apply to a man on long-term clinical testosterone. They were measured in 1,549 healthy men with normal baseline counts on monitored regimens. Nobody has published the equivalent curve for years of clinical use.
• That clomiphene, letrozole, anastrozole or hCG improve the chance of a pregnancy in a man whose LH and FSH are normal. The 2026 review found no qualifying trial of the first three and no benefit for the fourth.
• That supplements, acupuncture or any specific diet raise testosterone enough to change a fertility outcome. No source retrieved for this article tested that.